This record provides bibliographic details and links to the original research. An editorial study breakdown is not available.
Read the original research
Amycretin, a novel, unimolecular GLP-1 and amylin receptor agonist administered subcutaneously: results from a phase 1b/2a randomised controlled study.
Lancet (London, England), 406(10499), 149-162
Citation
Dahl, Kirsten; Toubro, Søren; Dey, Sohan; Duque do Vale, Ruben; Flint, Anne; Gasiorek, Agnes; Heydorn, Arne; Jastreboff, Ania M; Key, Cassandra; Petersen, Signe Beck; Vegge, Andreas; Adelborg, Kasper. (2025). Amycretin, a novel, unimolecular GLP-1 and amylin receptor agonist administered subcutaneously: results from a phase 1b/2a randomised controlled study.. Lancet (London, England), 406(10499), 149-162. https://doi.org/10.1016/S0140-6736(25)01185-7